Modella AI and AstraZeneca link for cancer clinical development
By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.
Therapy Area
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer
Biocon’s Denosumab biosimilars gain EU marketing authorisation
Brii Biosciences and Joincare sign licence agreement for BRII-693
BioVersys and Shionogi agree to develop ansamycin leads
Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma
Ligand’s LNHC concludes merger with CHRO
FDA approves Dizal’s Zegfrovy to treat adults with NSCLC
